Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoka T, Yokoyama I
Eur J Cancer Clin Oncol. 1983 Aug;19(8):1053-65. doi: 10.1016/0277-5379(83)90028-7.
A clinical evaluation of arterial infusion of high-molecular-weight antitumor agent SMANCS dissolved in lipid lymphographic agent (thiodol) in 44 patients with mostly unresectable hepatoma is described. The treatment regimen demonstrated significant merits both therapeutically and diagnostically. Marked antitumor effects were shown in the decreased serum alpha-fetoprotein levels (86% of cases) and tumor size (95% of cases), and in survival period and histological findings. Furthermore, there was increased diagnostic sensitivity using CT scan, plain X-rays or ultrasound. The procedure of selective arterial administration of 3-4 mg of SMANCS in 3-4 ml of ethiodol per dose was simple to perform and was required only once every 3-4 weeks. Both ethiodol and the drug accumulated more selectively in tumor than in any other tissues and their activity remained for more than 3 weeks. Only minimal side-effects were associated with SMANCS and ethiodol during this study.
本文描述了对44例大多无法切除的肝癌患者进行的一项临床评估，这些患者接受了溶解于脂质淋巴管造影剂（碘油）中的高分子量抗肿瘤药物丝裂霉素（SMANCS）的动脉灌注治疗。该治疗方案在治疗和诊断方面均显示出显著优点。血清甲胎蛋白水平降低（86%的病例）、肿瘤大小减小（95%的病例）、生存期延长以及组织学检查结果均显示出明显的抗肿瘤效果。此外，使用CT扫描、普通X光或超声检查时，诊断敏感性有所提高。每剂在3 - 4毫升碘油中选择性动脉注射3 - 4毫克SMANCS的操作简单，每3 - 4周只需进行一次。碘油和药物在肿瘤中的蓄积比在其他任何组织中更具选择性，且其活性可维持超过3周。在本研究中，SMANCS和碘油仅产生极小的副作用。
